Business Context and Reporting Period
This Form 8-K is filed by Nuvilex, Inc. (noted in metadata as Pharmacyte Biotech, Inc.) for the reporting period of May 27, 2011. The company is incorporated in Nevada and maintains its principal executive offices in Scottsdale, Arizona.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance issues rather than financial performance data.
Material Changes
On May 27, 2011, the Company received a Cease Trade Order from the British Columbia Securities Commission (BCSC). Trading of the Company's securities on the British Columbia Securities Exchange ceased as a result. The BCSC cited the Company's failure to file press releases and quarterly financial reports as required under Part 7 of NI 51-502 and section 5(b) of BCI 51-509. The Company stated it was unaware of these filing obligations until an analyst report was inadvertently emailed to Canadian residents, triggering the requirement.
Outlook, Risks, and Management Commentary
Management notes that Nuvilex has relatively few Canadian shareholders and that there was minimal trading of its securities on the British Columbia Securities Exchange prior to the order. Consequently, the Company does not anticipate that the Cease Trade Order will have a material effect on its operations or liquidity. The primary risk identified is the regulatory non-compliance in British Columbia, which has been addressed by the cessation of trading in that jurisdiction.
Investor Verification Checklist
- Verify the current trading status of Nuvilex, Inc. securities on the British Columbia Securities Exchange.
- Confirm whether the Company has subsequently filed the missing press releases and quarterly reports with the BCSC to potentially lift the Cease Trade Order.
- Review the Company's shareholder registry to assess the actual number of Canadian shareholders and the potential impact of the trading halt.
- Check for any other regulatory actions or cease trade orders in other jurisdictions.